Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity
Bloomberg 2026-07-01 01:41:28
Context: Biotechnology company BridgeBio Pharma Inc. has secured a $1 billion preferred equity investment from Sixth Street Partners and KKR & Co. The deal was confirmed by people with knowledge of the matter, although the exact terms and timing of the investment were not disclosed.
Key Facts
- Sixth Street Partners and KKR & Co. have agreed to provide $1 billion of preferred equity to BridgeBio Pharma Inc., as confirmed by people with knowledge of the matter.
- The investment is specifically in the form of preferred equity, which is a type of financing that has a higher claim on assets and dividends than common equity.
- BridgeBio Pharma Inc. is a biotechnology company that has been supported by prominent investors, with this latest deal highlighting the significant financial backing it has received.